Drug
Beta-lapachone clinical trials
Also written ARQ 501 and MB12066.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (6) · Yungjin Pharm. Co., Ltd. (4)
Studies
Open first, then newest update. How each study uses beta-lapachone is read from its arms, and is right about nine times in ten.
Testing it · 10
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy VolunteersCompletedPhase 1Yungjin Pharm. Co., Ltd.NCT01285388Written as MB12066
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male VolunteersCompletedPhase 1Yungjin Pharm. Co., Ltd.NCT02338856Written as MB12066 200mg
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy VolunteersCompletedPhase 1Yungjin Pharm. Co., Ltd.NCT01444677Written as MB12066
- Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except CirrhosisTerminatedPhase 2Yungjin Pharm. Co., Ltd.NCT02029586Written as MB12066 200mg
- An Extension Study for Patients Previously Treated With ARQ 501CompletedPhase 1/2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00622063Written as ARQ 501
- An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid TumorsCompletedPhase 1ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00524524Written as ARQ 501
- Safety and Efficacy Study of ARQ 501 in Adult Patients With LeiomyosarcomaCompletedPhase 2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00310518Written as ARQ 501
- A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and NeckCompletedPhase 2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00358930Written as ARQ 501
- ARQ 501 in Combination With Docetaxel in Patients With CancerCompletedPhase 1ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00099190Written as ARQ 501
- ARQ 501 in Subjects With CancerCompletedPhase 1ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00075933Written as ARQ 501
Codes
What other systems call beta-lapachone · ClinicalTrials.gg INT002606
- MeSH (NLM) C014638beta-lapachoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6N4FA2QQ6ALAPACHONEConfirmed FDA, NLM, Wikidata
- Wikidata Q27089386lapachoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C28694LapachoneOne source FDA
- DrugBank DB11948One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C014638 | beta-lapachone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6N4FA2QQ6A | LAPACHONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27089386 | lapachone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C28694 | Lapachone | One source FDA |
| DrugBank | DB11948 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.